You're probably right. A company with a successful consumer division, pipelines for cancer drugs, ischaemia drugs, fibrosis drugs, kidney disease drugs, stakes in veterinary medicine, bone disorders, biomarkers, and whatnot - a company like that may be trading at $10 per share and a billion dollar market cap some day in the future and still be considered cheap.
Oh am I only dreaming, or is this burning an eternal flame?
Evolis display at Soul Pattinson Pitt St Sydney, page-16
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
